Immuneering (NASDAQ:IMRX) Rating Increased to Hold at Wall Street Zen

Immuneering (NASDAQ:IMRX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms have also recently issued reports on IMRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Immuneering in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Stock Performance

IMRX opened at $5.33 on Friday. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08. The firm’s fifty day moving average is $5.22 and its 200 day moving average is $6.08. The stock has a market cap of $344.16 million, a price-to-earnings ratio of -2.99 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Immuneering will post -1.86 earnings per share for the current year.

Insider Activity

In related news, Director Thomas J. Schall purchased 21,645 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was bought at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the transaction, the director owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the purchase, the director directly owned 135,441 shares of the company’s stock, valued at $589,168.35. The trade was a 17.32% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 51,819 shares of company stock worth $234,472 over the last 90 days. Corporate insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Several institutional investors have recently modified their holdings of IMRX. Sanofi purchased a new stake in Immuneering during the 3rd quarter valued at $18,960,000. Iridian Asset Management LLC CT bought a new stake in Immuneering in the third quarter worth $1,926,000. Monashee Investment Management LLC purchased a new position in Immuneering during the third quarter worth $2,100,000. Kingsview Wealth Management LLC bought a new position in Immuneering during the second quarter valued at $47,000. Finally, TD Asset Management Inc bought a new position in Immuneering during the third quarter valued at $1,016,000. 67.65% of the stock is owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.